EnterNext accueille Esperite N.V. à l’occasion de sa cotation secondaire sur Euronext Paris

Paris – 7 July 2014 – EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs^{^[1]}, today announced the listing of Esperite NV in Paris, leader in stem-cell processing and the largest private cryo-conservation centre for stem cells in Europe. This is a secondary listing in Compartment C of Euronext Paris' regulated market. Already listed on Euronext Amsterdam's regulated market, the company took advantage of the listing to change its name from Cryo-Save Group to Esperite NV.

Founded in 2000, Esperite NV is a major player in the processing and cryo-conservation of stem cells and stores more than 260,000 samples from umbilical cord blood and cord tissue. Esperite NV has cryo-preserved samples from over 70 countries on six continents, with ultra-modern processing and storage facilities in Belgium, Switzerland, Dubai, South Africa and Portugal, thereby contributing to the treatment of numerous diseases.

Esperite NV was listed through the admission to trading of 9,728,692 ordinary shares making up its equity on Euronext Paris' regulated market. The shares of the company began trading under the ticker symbol "ESP" on 4 July 2014, on Euronext Paris and Amsterdam.

Market capitalisation stood at around €17 million on the day of listing.

"We extend a warm welcome to Esperite NV, a key life sciences company, on the occasion of its listing on Euronext Paris.This secondary listing illustrates the close ties between our markets in Europe, which use a single order book and enable mid-cap companies to access a larger pool of investors to meet their financing need and increase their visibility," said Eric Forest, Chairman and CEO of EnterNext.

Frédéric Amar, CEO of Esperite NV, added, "We are delighted to join Euronext Paris, Europe's most active trading platform for life sciences companies. Our listing on this market reflects our ambition in the sector and represents a new milestone in our strategy regarding regenerative and predictive medicine."

To mark the listing, Frederic Amar rang the bell to open the financial market in Paris, accompanied by his staff, advisers and EnterNext.

_{^[1]Small and medium-size companies}

Press Release Footer

About Euronext
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €7.1 trillion in market capitalisation as of end March 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

_{Disclaimer

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.}

_{This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.}